Latest Breaking News On - For vitargus - Page 1 : comparemela.com

AiBtl BioPharma Inc Acquired TT Life Company, Valued at $8 33M, With 1 66M AiBtl Shares at $5 per Share

AiBtl BioPharma Inc Acquired TT Life Company, Valued at $8 33M, With 1 66M AiBtl Shares at $5 per Share
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

United statesStanford universityRussman jaimesLeeds chowUttam patilSinai medical centerCompany annual report on formExchange commissionMalaysian import trading companyTaiwanese direct sales companyUniversity of california at san franciscoBiopharma incAsia economic development zoneTt life companyAibtl biopharma incSales company

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33 5M and Royalties up to $60M

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33 5M and Royalties up to $60M
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesStanford universityJerry changUttam patilLeeds chowCompany annual report on formCompany ophthalmologyUniversity of california at san franciscoSinai medical centerBiofirst corporationHealthcare analyst incForseecon eye corporationBiopharma incExchange commissionLicensed productHealthcare analyst

ABVC BioPharma, Inc CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

ABVC BioPharma, Inc CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesStanford universityUttam patilLeeds chowSinai medical centerCompany annual report on formBiopharma incUniversity of california at san franciscoExchange commissionSan franciscoCedars sinai medicalFor vitargusAnnual reportQuarterly reports

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

FREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) via NewMediaWire ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to license certain of its healthcare-related expertise ("Know-How") to Senior Paradise, Inc. ("SPI"), who will also lease certain of the Company's properties (the "Land") for further development relat

United statesStanford universityLeeds chowGreg hylandErik hillAsia pacificSenior paradise incBiopharma incUniversity of california at san franciscoHow to senior paradise incSinai medical centerCompany annual report on formNational sector lead of healthcareExchange commissionSenior paradiseCapital markets

ABVC Acquires $2 96 Million Worth of Land in Asia with Stocks Priced at $3 50 per Share

FREMONT, CA, Feb. 08, 2024 via NewMediaWire – ABVC BioPharma, Inc. , a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and.

Stanford universityUnited statesSan franciscoErik hillUttam patilLeeds chowAsia pacificNational sector lead of healthcareUniversity of californiaExchange commissionGlobenewswire incSinai medical centerCompany annual report on formBiopharma incTaoyuan cityGood agricultural practices